GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...
Incyte axed three prospects to focus on “high-value programs,” its CEO said. Elsewhere, MapLight priced an IPO during the ...
The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback